CTI.L Regulatory News (CTI)

Cathay International Holdings Limited

("Cathay" or the "Company")

Notice of Special General Meeting ("SGM")

Hong Kong, 30 August 2017 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China ("PRC"), today announces that a Special General Meeting ("SGM") will be held at the Hong Kong Office of the Company at Suites 1203-4, 12/F., Li Po Chun Chambers, 189 Des Voeux Road Central, Hong Kong on 22 September 2017 at 10:00 a.m. (Hong Kong time) for the purpose of considering and, if thought fit, passing the following resolutions which will be proposed as Ordinary Resolutions.

Ordinary Resolutions

1. To re-elect Mr. Sum Soon Lim as Non-Executive Director, who retires by rotation, in accordance with Bye-Law 84 of the Company's Bye-Laws.

2. To re-elect Mr. Kenneth K. Toong as Non-Executive Director, who retires by rotation, in accordance with Bye-Law 84 of the Company's Bye-Laws.

BY ORDER OF THE BOARD

Yip Pui Ling Rebecca

Company Secretary

The purpose of the SGM is to consider and, if thought fit, pass the ordinary resolutions required to re-elect Mr. Sum Soon Lim and Mr. Kenneth K. Toong ("Further Re-Election Resolutions"). The Further Re-Election Resolutions are required because: (i) at the Company's Annual General Meeting held on 21 June 2017, Messrs Sum Soon Lim and Kenneth K. Toong, both independent directors for the purposes of the UK Corporate Governance Code, retired as directors by rotation and had sought re-election of such directorships; and (ii) the resolutions relating to their respective re-elections were approved by a majority of votes cast by all shareholders but were not approved by a majority of votes cast by the independent shareholders. Accordingly, and pursuant to Listing Rule 9.2.2F and the guidance note at Listing Rule 9.2.2D, an SGM will now be held on 22 September 2017.

- ENDS -

For further enquiries, please contact:

About Cathay 

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the growing healthcare sector in the PRC. The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high- growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.